Cellular and Molecular Neurobiology – Stem Cells
Rebecca Matsas | Department of Neurobiology
Head of Laboratory
Our long-running research has focused on nervous system development and regeneration aiming at translational approaches for the treatment of neurodegenerative diseases and neurotrauma. We have been studying the biology of neural stem cells, especially mechanisms regulating proliferation versus differentiation, and have developed therapeutic cell transplantation approaches in pre-clinical animal models of neurodegeneration.
Our approaches integrate techniques of cell and animal modeling, histopathology, bioimaging, molecular biology and genetics, biochemistry, ex vivo and in vivo gene therapy with viral vectors.
We have established a microsurgery and neural stem cell transplantation Unit for rodent models of neuropathology in conjunction with histopathology and behavioural suites to monitor anatomical and functional recovery.
We are closely connected and have contributed to the establishment of the Institute’s Bioimaging Unit through acquisition of new instrumentation and know-how development.
More recently our group has been using neural cells derived from human pluripotent stem cells to model human brain development and degeneration in conditions such as Parkinson’s Disease, and has established the Institute’s Human Embryonic and Induced Pluripotent Stem Cell Unit.
Understanding the mechanisms underlying human brain development and disease has long been hampered by limited access to the living brain and the inability to isolate and maintain live human neurons. The advent of human stem cells in combination with cellular reprogramming technologies has opened new perspectives in the field of brain research. Human embryonic stem cells and induced pluripotent stem cells (iPSCs) generated by reprogramming of differentiated somatic cells to pluripotency, provide for the first time the opportunity to foster live human neurons and glial cells in the laboratory.
Patient-derived model for Parkinson’s disease pathogenesis: a platform for mechanistic studies and the identification of disease-modifying compounds
A major focus of research in the past few years has been the generation of iPSCs from skin fibroblasts of patients with familial Parkinson’s disease bearing the p.A53T mutation in the α-synuclein protein (G209A in the SNCA gene) to elucidate disease mechanisms and identify new therapeutic targets. Directing their differentiation to neurons, we developed a 2-D clinically relevant model displaying distinct disease phenotypes that has been an instrumental biological system for mechanistic studies of disease pathogenesis and drug discovery (Kouroupi et al PNAS 2017; Taoufik et al Open Biol 2018; Grudina, Kouroupi et al Neurobiol Dis 2019; Elkouris, Kouroupi et al Front Cell Neurosci. 2019 ; Kouroupi et al Int J Mol Sci 2020; Int J Dev Biol. 2021; Kim… Kouroupi et al Front Microbiol. 2021; Antoniou et al npj Parkinson’s Disease 2022).
Col. Dr Regis Grailhe
High Content imaging and compound library screening for identification of novel therapeutics for Parkinson’s disease
The p.A53T system has been adapted for high-content imaging and compound library screening, which identified the multi-kinase inhibitor BX795 as a promising neuroprotective molecule and candidate therapeutic. Proteomics profiling mapped the molecular pathways underlying the protective effects of BX795, comprising a cohort of 118 protein-mediators of the core biological processes of RNA metabolism, protein synthesis, modification and clearance, and stress response, all linked to the mTORC1 signaling hub. In agreement, expression of human p.A53T-αSyn in neuronal cells affected key components of the mTORC1 pathway resulting in aberrant protein synthesis that was restored in the presence of BX795 with concurrent facilitation of autophagy. Taken together, we have identified a promising small molecule with neuroprotective function as candidate therapeutic for PD and possibly other protein conformational disorders (Antoniou et al 2022 npj Parkinson’s disease). Research is ongoing to identify BX795 direct targets.
In vivo modeling of p.A53T-aSyn pathology
In this study we investigated the in vivo fate and phenotypes of patient-derived p.A53T-iPSC derived neurons after transplantation in a chemically-induced mouse model of Parkinson’s disease established by unilateral intrastriatal 6-hydroxydopamine injection in the immunosuppressed NOD/SCID strain. We found that mutant cells could survive and differentiate in vivo over a 12-week period. However, at this time point they displayed significantly increased levels of α-synuclein signaling a first step towards pathology, and showed compromised integration within the host tissue. This data imply caution regarding the long-term consequences of autologous transplantation as a therapeutic strategy for Parkinson’s disease patients (Zygogianni et al Methods Mol Biol. 2020; Neurochem Res. 2019).
Development of a human stem cell-based model of human brain development: investigation of human-associated traits of neurodevelopment
An iPSC-based system has been generated for modeling human brain development in 2D cultures. Integrated mRNA/miRNA transcriptome analysis at distinct stages of directed neuronal differentiation identified miR-934, a human-associated miRNA that displays a stage-specific expression pattern during progenitor expansion and early neuron generation. We demonstrated the biological relevance of this finding by comparison with data from early to mid-gestation human cortical tissue. miR-934 directly controls progenitor to neuroblast transition and impacts on neurite growth of newborn neurons. Its inhibition results in profound global transcriptome changes associated with neurogenesis while affecting the expression of genes associated with the subplate zone, a transient compartment most prominent in primates that emerges during early corticogenesis. Our work highlights mir-934 as a novel regulator of early human neurogenesis with potential implications for a species-specific evolutionary role in brain function (Prodromidou and Matsas Cell Mol Life Sci 2021; Prodromidou et al. eLife 2020; Prodromidou and Matsas Front Cell Neurosci. 2019).
DISEASE MODELING AND DRUG SCREENING PLATFORM
This new core facility initiative, aims to provide capacity for high-throughput high-content imaging and phenotypic screening, using cellular disease models and tissue organoids for investigation of poorly understood complex human conditions, such as neurodegenerative diseases.
Recent advances in cell reprogramming technologies have facilitated the generation of patient-derived models for neurodegenerative diseases and the identification of early, potentially triggering, pathological phenotypes while they provide amenable systems for drug discovery.
The Platform aims at combining disease-modeling, automated high-content imaging and phenotypic analysis, compound library screening and multi-electrode array electrophysiological recordings for integrated morphological, molecular, cellular and functional studies.
Setting-off in relevance to neurodegenerative diseases, the platform aims to provide expertise for collaborative ventures and services to the scientific community, and expand its activities in infectious and chronic diseases.
Platform development is supported by the Hellenic Foundation for Research & Innovation (HFRI) ELIDEK; 1st Call for H.F.R.I. Research Projects to Support Faculty Members & Researchers and the Procurement of High-Value Research Equipment (H.F.R.I grant 1019-DiseasePhenoTarget to R. Matsas).
Hellenic Foundation for Research and Innovation (HFRI) 2021-2024: Development of a multiparametric morphofunctional platform to uncover disease mechanisms and druggable targets in patient derived cells: study of neuron-glia dynamics in alpha synuclein-mediated pathologies» (1019-DiseasePHENOTarget). PI: R. Matsas
Hellenic General Secretariat for Research and Innovation (GSRI) Operational Programme Competitiveness, Entrepreneurship and Innovation 2014-2020 (EPAnEK – NSRF 2014-2020), 2021-2023: Systematic development and commercial exploitation of novel compounds inhibiting alpha-synuclein aggregation ( AlphaSyn MIS 5131418) PI for HPI: R. Matsas; Coordinator: G. Skretas
Urgence COVID-19 Fundraising Campaign of Institut Pasteur, 2020-2021: Investigation of SARS-CoV-2 mechanism of pathogenicity using organoids produced from human induced pluripotent stem cells (hiPSC)». PIs PCB. Beltrão-Braga (Brazil), EL. Durigon (Brazil), and R. Matsas (HPI)
Flagship Action for Research on Neurodegenerative Diseases on the Basis of Personalized Medicine. HPI coordinator, R. Matsas
Pasteur Joint International Research Unit Partnership within IPIN, PIU2020-2025: Creation of a Virtual Research Unit for Studies in Neurodegenerative Diseases. PIs Rebecca Matsas (HPI) and Chiara Zurzolo (IP-Paris)
Partnership Agreement for the Development Framework 2014-2020 for a 15-month project: Investigation of the effect of the microneurotrophin BNN-20 on Parkinson’s Disease patient induced pluripotent stem cell-derived neurons and on the success of stem cell transplantation in an animal model of the disease (Deputy Academic Advisor: G. Kouroupi)
Hellenic Foundation for Research and Innovation (HFRI) Project for Postdoctoral Researchers 2018-2021: Mechanisms of synaptic dysfunction in human induced pluripotent stem cell-based 2D- and 3D-models of familial Parkinson’s disease (PARKINSynapse). Principal Investigator: Georgia Kouroupi
Institut Pasteur Direction du Développement, GRAND PROGRAMME FÉDÉRATEUR M&B, MICROBES & BRAIN PROJECTS 2016: SEEDS FOR INNOVATION 2017-2018: In vivo models of brain infection by Gram+ bacteria: from barrier crossing to neural stem cell (InFeSteR). PIs: Pauline Spéder-Murphy (coordinator); Shaynoor Dramsi; Rebecca Matsas.
Stavros Niarchos Foundation Grant 2016-2020: Development of innovative biological products and services for infectious and neurodegenerative diseases Coordinated by R. Matsas and V. Miriagou
Institut Pasteur Transversal Research Program 2015-2018 PTR-523: Mechanisms of pathological A53T-alpha-synuclein transmission in human iPS-derived neurons. Coordinated by R. Matsas; Participants: C. Zurzolo, PM Lledo and F. Lazarini IP-Paris
Fondation Santé Grant 2014-2016: An integrated genome-wide miRNA-mRNA approach in a human stem cell-based model of neurodevelopment and disease.
Greek Ministry of Education 2012-2015: EXCELLENCE GRANT I-2272 – Modeling Parkinson’s disease by conversion of fibroblasts to dopaminergic neurons.
Greek General Secretariat for Research and Technology 2011-2015: Cooperation GRANT 09SYN-21–969 – Mechanisms of Induced Pluripotency: From Transcriptional Noise to Stem Cell Therapies.
Greek General Secretariat for Research and Technology 2013-2015 KRHPIS GRANT InfeNeuTra – MIS450598: Infectious and Neurodegenerative diseases: From study of basic mechanisms to development of translational research towards prevention and therapy.
Greek General Secretariat for Research and Technology 2013-2015: THALES GRANT KA3578 “Mitochondrial Dysfunction in Neurodegenerative Diseases”
Institut Pasteur Transversal Research Program Grant 2013-2015 PTR-417: Parkinsonian patient-derived dopaminergic neurons for disease modeling and drug discovery. Coordinated by R. Matsas; Participants: D. Bohl IP-Paris, R. Grailhe IP-Korea.
Empeirikion Foundation 2013-2014 Generation of patient-derived induced pluripotent stem cells
Fondation BNP Paribas 2010-2013: Use of human stem cells for the treatment of neurodegenerative diseases and injuries of the brain and spinal cord.
EU FP7 Program Grant 264083 NEUROSIGN 2010-2013: Development of a Centre of Excellence in Neurosignalling (raised by Tzartos – coordinator, Matsas and Probert).
Bodossaki Foundation Award, 2009-2010: Establishment of a Stem Cell and Transplantation Facility.
Wings for Life Foundation for Spinal Cord Research 2006-2007: Therapeutic potential of Schwann cells genetically engineered to express PSA after transplantation in the lesioned mouse spinal cord.
Greek General Secretariat for Research and Technology 2005-08: Development of infrastructure in cutting-edge technologies for innovative diagnostic and therapeutic strategies. (Matsas, Mamalaki, Probert and Soteriadou co-PIs)
Greek General Secretariat for Research and Technology Programme PENED, 2005-2007. Application of the neuroprotective factor IGF1 for the treatment of brain trauma and neurodegeneration (F. Stylianopoulou – coordinator)
Greek General Secretariat for Research and Technology Programme EPAN, 2004-2006 Neural Stem Cell Therapies for Neurodegenerative Diseases: Determination of a “molecular signature” for neuronal fate, YB26:
Greek General Secretariat for Research and Technology Programme EPAN, 2004-2006. Baculovirus Artificial Chromosomes (BVACs) and Technologies for Gene Therapy and Continuous High-Level Expression of Therapeutic Proteins in Insect Production Systems, YB11.
EU Training and Mobility Programme – Neurosciences, 2003-2005. Role of calcium mobilization in neuronal differentiation: novel aspects of single cell and organellar calcium signals. QLG2-CT-2002-51680:
EU Quality of Life Programme – Neurosciences, 2000-2003. Genes controlling neuronal specification and differentiation QLG3-CT-00072:
EU Quality of Life Programme – Neurosciences, 2000-2003 Engineering neural precursors for myelin repair. QLG3-CT-00911:
2017 to date: Nominated member of the General Assembly of ELIDEK, the Greek Foundation for Research and Innovation
2015: Elected EMBO Member; Nominated by EMBO member of AcademiaNet
2015 to date: Member of the International Advisory Board of the Hellenic Pasteur Institute
2011-2014: Nominated by the Ministry of Education member of the Life Sciences Section of the National Scientific Council for Research and Technology
2010: Fulbright Foundation Award for Academic Excellence
2010-2014: Elected Member of the Schools Committee of the Federation of European Neuroscience Societies (FENS)
2005: Decorated Chevalier de l’Ordre National du Mérite by the French Republic
2002-2005: National Delegate in the 6th Framework Program: Life Sciences & Biotechnology for Health
2003-2005: Member of the Executive Bureau of the International Network of Pasteur Institutes and Regional Representative of the European Pasteur Institutes
1992: EMBO Research Fellow
1980-2005: Medical Research Council UK Research Fellow
1994 to date: National Delegate in the European Neuroglial Network
2016: Fulbright Visiting Scholar to Sanford Burnham Prebys Medical Discovery Institute, San Diego, USA and Dr. Fossati’s lab at the New York Stem Cell Institute
2017: Travel grant to attend the 2nd Croucher course on Advanced Imaging in Hong Kong.
2016: EMBO travel grant to attend the EMBO Workshop on Dendritic Anatomy, Molecules and Function
2013: Research Fellowship from the Theodore-Theochari Cozzika Foundation
2012: EMBO Short Term Fellowship to visit Mellita Schachner lab, Hamburg, Germany
2018: Best Oral Presentation Award, ‘Impaired autophagy and synaptic defects in a human iPSC-based model of familial Parkinson’s disease’, 3rd Congress of the Hellenic Society of Gene Therapy and Regenerative Medicine, Thessaloniki, Greece
2017: Selected for the Neuroscience School of Advanced Studies: Neural Stem Cells and Brain Repair, 20-27 May 2017, Tuscany, Italy
2016: Best Poster Presentation Award ‘Rescue of the pathological phentoype using small molecules targeting α-synuclein in a patient-specific cell-based model of Parkinson’s disease’, Kouroupi G., Taoufik E., Vlachos I. S., Tsioras K., Antoniou N., Wrasidlo W., Vekrellis K., Stefanis L., Bregestovski P., Hatzigeorgiou A. G., Masliah E., Matsas R. 2nd Symposium of Postgraduate Students and Postdoctoral Researchers, Hellenic Pasteur Institute, Athens, Greece
2014: Travel Award, International Society for Stem Cell Research (ISSCR) for 12th Annual Meeting of the International Society for Stem Cell Research, Vancouver, Canada
2010: Best Oral Presentation Award, ‘Lentivirus-mediated expression of insulin-like growth factor-I promotes neural stem cell proliferation and enhances their potential to generate neurons’, Kouroupi G., Lavdas A. A., Gaitanou M., Thomaidou D., Stylianopoulou F., Matsas R. 5TH Meeting of the Hellenic Society for Bioscientists, Athens, Greece
2010: Best Oral Presentation Award, ‘Lentivirus-mediated expression of insulin-like growth factor-I promotes neural stem cell proliferation and enhances their potential to generate neurons’, Kouroupi G., Lavdas A. A., Gaitanou M., Thomaidou D., Stylianopoulou F., Matsas R. Neuroscience Days of the Hellenic Society for Neuroscience (HSfN), Athens, Greece
2009: Travel Award, “Athinoula A. Martinos” Foundation for 41st Meeting of the European Brain and Behaviour Society (EBBS) and the 23rd Meeting of the Hellenic Society for Neuroscience (HSfN), Rhodes, Greece
2018: ‘George Stamatoyannopoulos’ Award for best project ‘MicroRNA-934 is a novel regulator of early human neurogenesis with a prospective evolutionary role in brain development’, K. Prodromidou, I. S. Vlachos, M. Gaitanou, G. Kouroupi, A. G. Hatzigeorgiou, R. Matsas, 3rd Congress of the Hellenic Society of Gene Therapy and Regenerative Medicine, Thessaloniki, Greece
2016: ‘Athanasios Loukeris’ annual award for best oral presentation/project of a young researcher of Hellenic Pasteur Institute ‘mir-934 is a novel regulator of early human neurogenesis’ Kanella Prodromidou, Ioannis Vlachos, Georgia Kouroupi, Maria Gaitanou, Era Taoufik, Artemis Hatzigeorgiou and Rebecca Matsas.
2016: Travel grant for EMBO Workshop: Nuclear Function and Cell Fate, 18-22 September 2016
2011: Best Oral presentation Award at the 62nd Conference of the Hellenic Society for Biochemistry and Molecular Biology (HSBMB) ‘The cellular prion protein is required for NCAM-induced neuronal differentiation’ Prodromidou K., Papastefanaki F., Sklaviadis T., Matsas R.,
2015: ‘Athanasios Loukeris’ annual award for best oral presentation/project of a young researcher of Hellenic Pasteur Institute, “A nonsense point mutation in a novel SLC25 family member of mitochondrial carriers causes severe recessive neurological disease and epilepsy in mice”, Aikaterini Segklia, Maria-Eirini Terzenidou, Florentia Papastefanaki, Eleni Douni and Rebecca Matsas, 1st Young Scientists Forum, 24/09/2015, Hellenic Pasteur Institute
2017: Best Poster Award, 2nd Congress of Gene Therapy and Regenerative Medicine, Athens “High Content screening analysis in an induced pluripotent stem cell-based model of familial Parkinson’s disease reveals a kinase inhibitor that enhances the differentiation to dopaminergic neurons” Antoniou N, Kouroupi G, Taoufik E, Grailhe R, Matsas R
2016: Grant for participation in the Course: High Content Assay for Target Discovery Using RNAi technology, 9-13 May 2016, Institute Pasteur Korea
2015: Calmette-Yersin grant: Identification of therapeutic targets for Parkinson’s disease using a humaninduced pluripotent stem cell-based model. Collaborative proposal between IP-Hellenic and IP-Korea. Responsible Scientists: Rebecca Matsas and Regis Grailhe. Student mobility: Nasia Antoniou, September 2015-January 2016 and May 2016-August 2016
2016: Calmette-Yersin grant to participate in the IP-Paris Course “Principles
and Applications of Fluorescence Microscopy” (22/02-04/03/2016).
2015: Best poster award in 2nd Young Scientists Forum with title: “Development of a chimeric brain model for the study of A53T-alpha-synuclein pathology” Zygogianni O., Papastefanaki F., Kouroupi G., Koronaiou M., Taoufik E., Matsas R., Hellenic Pasteur Institute (24/09/2015)
2014: “miStem”, a project for the development of a spin-off/start-up company for biomarker and drug discovery in the field of neurodegenerative diseases was selected among the top 10 projects (out of 205 submitted) in the “Innovation Project Disrupt, Startup, ScaleUp” competition organized by the Hellenic Association of Pharmaceutical Companies (SFEE)
The 10 finalist Startups:
- Τhe Hellenic EyeBank Demokritos “Grigoris Georgariou”
- Proteomarkers Biotech
- MeR Lab
- Biomarket, Medical Physiology Lab
- Amyndas Pharmaceuticals
The Laboratory of Cellular and Molecular Neurobiology has a track record in educational and training activities. In conjunction with the Biology Departments of the University of Athens and the University of Patras as well as the Medical School of the University of Athens, a large number of graduate students have performed their thesis towards an MSc or PhD degree. The researchers of the lab are actively involved in teaching in University post-graduate courses while they undertake undergraduate and post-graduate students for training and theses.
Faculty members of the lab are actively involved in the Athens International Master’s Programme in Neurosciences launched in 2017 as part of the Network of European Neuroscience Schools (NENS).
Also participation in the following Master’s Courses:
“Molecular Medicine – Neurobiology” of the Athens Medical School
“Applications of Biology in Medicine” of the Biology Department of the University of Athens
“Applied Neuroanatomy” of the Athens Medical School
“MA Animal Welfare, Ethics and the Law”, Department of Philosophy (NKUA) and the Hellenic Pasteur Institute
ORGANIZATION OF SELECTED SCIENTIFIC MEETINGS AND WORKSHOPS
1998 3rd European Meeting on Glial Cell Function in Health and Disease Athens
2000 4th European Meeting on Glial Cell Function in Health and Disease,
2001 FEBS/EMBO Advanced Course “From differentiation to death of nerve cells”
2002 5th European Meeting on Glial Cell Function in Health and Disease, Rome
2003 FENS/IBRO Winter School NEURAL STEM CELLS from specification and
nervous system patterning to therapies for neurodegenerative diseases,
2004 Modern Light Microscopy Techniques In Biomedical Research HPI, Athens
2009 9th European Meeting on Glial Cell Function in Health and Disease, Paris
2009 60th Meeting of the Hellenic Society for Molecular Biology and Biochemistry
2009 23rd Meeting of the Hellenic Society for Neuroscience Rhodes.
2011 10th European Meeting on Glial Cell Function in Health and Disease, Prague
2011 62nd Meeting of the Hellenic Society for Biochemistry and Molecular Biology
2011 International Society of Neurochemistry Meeting Athens
2013 11th European Meeting on Glial Cell Function in Health and Disease, Berlin
2012 REGPOT Neurosign Workshop “Animal models of neurodegeneration and
behavioral tests for assessment of motor and cognitive function” HPI,
2013 REGPOT Neurosign Workshop “Live Cell Imaging and Electrophysiology”
2013 26th Meeting of the Hellenic Neuroscience Society jointly with REGPOT
2015 12th European Meeting on Glial Cell Function in Health and Disease, Bilbao
2022 NECTAR (Network of CNS Transplantation and Restoration) Meeting Athens
OUTREACH ACTIVITIES AND MEDIA COVERAGE
Communicating science to the public is an important task of our lab. Here are some examples of open-to-the-public actions that we have participated in:
- 11th UniStem Day Worldwide “the long and fascinating trip of stem cell research”: An event dedicated to stem cell research for high school students, March 15th 2019, Hellenic Pasteur Institute
- Stem Cells: myth and reality Discussion. Megaron Plus 2014 (Dialogues: Science in our life)
- Parkinson’s disease: problems and prospects Discussion Megaron Plus 2015 (Dialogues: Science in our life)
- Theocharakis Foundation| Coffee with the researchers of the Hellenic Pasteur Institute (Café Merlin) 2016-2017
- European Researchers’ Night
- Athens Science Festival “Exploring the human brain and its diseases with stem cells”
- Brain Awarness Week (public events organized by the Hellenic Society for Neurosciences and the Dana Alliance for Brain Research)
- Educational and Social Action for Children Refugees of School Age “The HPI pasteurizes the microbe of xenophobia”, organized by the Hellenic Pasteur Institute in collaboration with the UNHCR (The UN refugee agency)
- New Greek government raises hopes for science. Nature, January 2015
- Greek crisis spurs research reforms Nature, July 2011
- Genetically Engineered Schwann Cells: Remyelination therapies of the injured or diseased central nervous system ΒΙΟ Volume 22, 2007
THE FOLLOWING OUTREACH ACTIVITIES ARE ONLY IN GREEK
- The Hub Science Events-2020: “Νέα βιολογία και ιατρική: Μια ανατρεπτική σχέση” Ομιλητές Μανώλης Δερμιτζάκης και Ρεβέκκα Μάτσα
- Τηλεοπτικά αφιερώματα για την επιστήμη: ΕΡΤ2 «Οι Δρόμοι της Ανάπτυξης» και κανάλι της Βουλής, αφιέρωμα για τα 100 χρόνια του ΕΙΠ στην εκπομπή Διαβουλεύσεις
- Εκδήλώση Pint of Science-2019: “Μια κανάτα… βλαστοκύτταρα και… «καλά γεράματα”! Ρ. Μάτσα
- Εγκέφαλοι μινιατούρες και θεραπείες του μέλλοντος. Διάλεξη Γ. Κουρούπη,
Εκδήλωση “Εξερευνώντας τον Εγκέφαλο”, Κέντρο Πολιτισμού Ίδρυμα Σταύρος Νιάρχος, Μάρτιος 2018, http://exploringthebrain.gr/
- Επιδιορθώνοντας τον εγκέφαλο: βλαστικά κύτταρα. Διάλεξη Ρ. Μάτσα, Όμιλος Φίλων Παστέρ – Café Scientific Ίδρυμα Εικαστικών Τεχνών και Μουσικής Β&Μ Θεοχαράκη, Αθήνα 2016
- Διερευνώντας τη νόσο Πάρκινσον με βλαστικά κύτταρα. Διάλεξη Ρ. Μάτσα, Megaron Plus 2014
- Επιδιορθώνοντας τον εγκέφαλο: βλαστικά κύτταρα. Διάλεξη Ρ. Μάτσα, Όμιλος Φίλων Παστέρ Λιβαδειά, 2015
- Βλαστικά κύτταρα: Μύθος και πραγματικότητα. Διάλεξη Ρ. Μάτσα, Megaron Plus 2014
- Νέο Εθνικό Κέντρο Αριστείας για τις Νευροεπιστήμες. Καθημερινή 2014
- Η χρήση των βλαστικών κυττάρων σε κυτταρικές θεραπείες νευροεκφυλιστικών ασθενειών. Διάλεξη Μ. Γαϊτάνου, Ναυτικό Νοσοκομείο Σαλαμίνας, 2012
- Συνδυαστικές θεραπείες με γενετικά τροποποιημένα κύτταρα. Ημερησία 2009
- Η έρευνα για την υγεία στην Ελλάδα. Βήμα Ιδεών, Νοέμβριος 2008
- Θα μπορέσουμε να θεραπεύσουμε τις παθήσεις του εγκεφάλου; Βήμα Ιδεών, Ιούλιος 2008
- Έχουν τον έλεγχο των πιο κρυφών κυττάρων σου. Ελεύθερος Τύπος 2008
- Κύτταρα διασώστες στη σπονδυλική στήλη. Βήμα Science 2007
- Λουί Παστέρ: Ο πατέρας της Μικροβιολογίας. «Ε» Ιστορικά 2007
Antoniou N, Prodromidou K, Kouroupi G, Boumpoureka I, Samiotaki M, Panayotou G, Xilouri M, Kloukina I, Stefanis L, Grailhe R, Taoufik E, Matsas R. High content screening and proteomic analysis identify a kinase inhibitor that rescues pathological phenotypes in a patient-derived model of Parkinson's disease. NPJ Parkinsons Dis. 2022 Feb 11;8(1):15. doi: 10.1038/s41531-022-00278-y. PMID: 35149677; PMCID: PMC8837749.2022
Kim S, Larrous F, Varet H, Legendre R, Feige L, Dumas G, Matsas R, Kouroupi G, Grailhe R, Bourhy H. Early Transcriptional Changes in Rabies Virus-Infected Neurons and Their Impact on Neuronal Functions. Front Microbiol. 2021 Dec 13;12:730892. doi: 10.3389/fmicb.2021.730892. PMID: 34970230; PMCID: PMC8713068.
Prodromidou K, Matsas R. Evolving features of human cortical development and the emerging roles of non-coding RNAs in neural progenitor cell diversity and function. Cell Mol Life Sci. 2021 Dec 18;79(1):56. doi: 10.1007/s00018-021-04063-7. PMID: 34921638.
Kouroupi G, Prodromidou K, Papastefanaki F, Taoufik E, Matsas R. Organoids: the third dimension of human brain development and disease. Int J Dev Biol. 2021 Oct 26. doi: 10.1387/ijdb.210158gk. Epub ahead of print. PMID: 34881786.
Papastefanaki F. Application of developmental principles for spinal cord repair after injury. Int J Dev Biol. 2021 Aug 9. doi: 10.1387/ijdb.210110fp. Epub ahead of print. PMID: 34549790.
Cheimonidi C, Grivas IN, Sesti F, Kavrochorianou N, Gianniou DD, Taoufik E, Badounas F, Papassideri I, Rizzi F, Tsitsilonis OE, Haralambous S, Trougakos IP. Clusterin overexpression in mice exacerbates diabetic phenotypes but suppresses tumor progression in a mouse melanoma model. Aging (Albany NY). 2021 Mar 10;13(5):6485-6505. doi: 10.18632/aging.202788. Epub 2021 Mar 10. PMID: 33744871; PMCID: PMC7993736.
Mladenovic Djordjevic AN, Kapetanou M, Loncarevic-Vasiljkovic N, Todorovic S, Athanasopoulou S, Jovic M, Prvulovic M, Taoufik E, Matsas R, Kanazir S, Gonos ES. Pharmacological intervention in a transgenic mouse model improves Alzheimer's-associated pathological phenotype: involvement of proteasome activation. Free Radic Biol Med. 2020 Dec 3:S0891-5849(20)31662-2. doi: 10.1016/j.freeradbiomed.2020.11.038. Epub ahead of print. PMID: 33279620.
Benmimoun B, Papastefanaki F, Périchon B, Segklia K, Roby N, Miriagou V, Schmitt C, Dramsi S, Matsas R, Spéder P. An original infection model identifies host lipoprotein import as a route for blood-brain barrier crossing. Nat Commun. 2020 Nov 30;11(1):6106. doi: 10.1038/s41467-020-19826-2. PMID: 33257684; PMCID: PMC7704634.
Kouroupi G, Antoniou N, Prodromidou K, Taoufik E, Matsas R. Patient-Derived Induced Pluripotent Stem Cell-Based Models in Parkinson's Disease for Drug Identification. Int J Mol Sci. 2020 Sep 26;21(19):7113. doi: 10.3390/ijms21197113. PMID: 32993172; PMCID: PMC7582359.
Zygogianni O, Kouroupi G, Taoufik E, Matsas R. Engraftable Induced Pluripotent Stem Cell-Derived Neural Precursors for Brain Repair. Methods Mol Biol. 2020;2155:23-39. doi: 10.1007/978-1-0716-0655-1_3.
Prodromidou K, Vlachos IS, Gaitanou M, Kouroupi G, Hatzigeorgiou AG, Matsas R. MicroRNA-934 is a novel primate-specific small non-coding RNA with neurogenic function during early development. Elife. 2020 May 27;9:e50561. doi: 10.7554/eLife.50561. Online ahead of print.
Prodromidou K, Matsas R. Species-Specific miRNAs in Human Brain Development and Disease. Front Cell Neurosci. 2019 Dec 18;13:559. doi: 10.3389/fncel.2019.00559. PMID: 31920559; PMCID: PMC6930153.
Tzortzopoulos A, Thomaidou D, Gaitanou M, Matsas R, Skoulakis E. Expression of Mammalian BM88/CEND1 in Drosophila Affects Nervous System Development by Interfering with Precursor Cell Formation. Neurosci Bull. 2019 Dec;35(6):979-995. doi: 10.1007/s12264-019-00386-5. Epub 2019 May 11. PMID: 31079319; PMCID: PMC6864003.
Grudina C, Kouroupi G, Nonaka T, Hasegawa M, Matsas R, Zurzolo C. Human NPCs can degrade α-syn fibrils and transfer them preferentially in a cell contact-dependent manner possibly through TNT-like structures. Neurobiol Dis. 2019 Sep 5:104609. doi: 10.1016/j.nbd.2019.104609.
Zygogianni O, Antoniou A, Kalomoiri M, Kouroupi G, Taoufik E, Matsas R. In vivo phenotyping of familial Parkinson’s disease with human induced pluripotent stem cells: a proof-of-concept study. Neurochem Res. 2019 Apr 15. doi: 10.1007/s11064-019-02781-w.
Elkouris M, Kouroupi G, Vourvoukelis A, Papagiannakis N, Kaltezioti V, Matsas R, Stefanis L, Xilouri M and Politis PK. Long non-coding RNAs associated with neurodegeneration-linked genes are reduced in Parkinson’s Disease patients. Front Cell Neurosci. 2019 Feb 22;13:58. doi: 10.3389/fncel.2019.00058. eCollection 2019.
Segklia K, Stamatakis A, Stylianopoulou F, Lavdas AA, Matsas R. (2019) Increased Anxiety-Related Behavior, Impaired Cognitive Function and Cellular Alterations in the Brain of Cend1-deficient Mice. Front Cell Neurosci. 12:497. doi: 10.3389/fncel.2018.00497. eCollection 2018
Gaitanou M, Segklia K and Matsas R. (2019) Cend1, a story with many tales: From regulation of cell cycle progression/exit of neuralstem cells to brain structure and function. Stem Cells International, in Press.
Taoufik E, Kouroupi G, Zygogianni O., Matsas R. Synaptic dysfunction in neurodegenerative and neurodevelopmental diseases: an overview of induced pluripotent stem cell-based disease models. Royal Society’s Open Biology, 2018.2018
Kouroupi G, Taoufik E, Vlachos IS, Tsioras K, Antoniou N, Papastefanaki F, Chroni-Tzartou D, Wrasidlo W, Bohl D, Stellas D, Politis PK, Vekrellis K, Papadimitriou D, Stefanis L, Bregestovski P, Hatzigeorgiou AG, Masliah E, Matsas R. (2017) Defective synaptic connectivity and axonal neuropathology in a human iPSC-based model of familial Parkinson's disease. Proc Natl Acad Sci USA, 114(18):E3679-E3688
Terzenidou Μ*, Segklia Α*, Kano Τ, Papastefanaki F, Karakostas A, Charalambous M, Ioakeimidis F, Papadaki M, Kloukina I, Chrysanthou-Piterou M, Samiotaki M, Panayotou G, Matsas R#, Douni E.# (2017) Novel Insights into SLC25A46 Related Pathologies in a Genetic Mouse Model. PLOS Genet. 13(4): e1006656. * equal first authors; # joint senior authors
Pallaki P., Georganta E., Serafimidis I., Papakonstantinou M., Papanikolaou V., Koutloglou S., Papadimitriou E., Agalou A., Tserga A., Simeonof A., Thomaidou D., Gaitanou M. and Georgoussi Z. (2017). A novel regulatory role of RGS4 in STAT5B activation, neurite outgrowth and neuronal differentiation Neuropharmacology (117):408-421.
Koutsoudaki PN, Stamatakis A, Papastefanaki F, Kouroupi G, Xingi E, Stylianopoulou F and Matsas R (2016) Neural stem/progenitor cells differentiate to oligodendrocytes, reduce inflammation and ameliorate learning deficits after transplantation in a mouse model of traumatic brain injury, GLIA 64(5):763-79.2016
Aravantinou-Fatorou K, Ortega F, Chroni-Tzartou D, Antoniou N, Poulopoulou C, Politis PK, Berninger B, Matsas R, Thomaidou D. (2015) Cend1 and Neurogenin2 Reprogram Mouse Astrocytes and Embryonic Fibroblasts to Induced Neural Precursors and Differentiated Neurons. Stem Cell Reports 5(3):405-18.
Papastefanaki F, Jakovcevski I, Poulia N, Djogo N, Schulz F, Martinovic T, Ciric D, Loers G, Vossmeyer T, Weller H, Schachner M, Matsas R. (2015) Intraspinal Delivery of Polyethylene Glycol-coated Gold Nanoparticles Promotes Functional Recovery After Spinal Cord Injury. Mol Ther 23(6):993-1002.
Papastefanaki F, Matsas R. (2015) From demyelination to remyelination: The road toward therapies for spinal cord injury. GLIA 63(7):1101-25.)
Prodromidou K, Papastefanaki F, Sklaviadis T, Matsas R. (2014) Functional cross-talk between the cellular prion protein and the neural cell adhesion molecule NCAM is critical for neuronal differentiation of neural stem/precursor cells. Stem Cells 32(6):1674-87.
Foka P, Karamichali E, Dalagiorgou G, Serti E, Doumba PP, Pissas G, Kakkanas A, Kazazi D, Kochlios E, Gaitanou M, Koskinas J, Georgopoulou U and Mavromara P. (2014). “Hepatitis C virus modulates lipid regulatory factor Angiopoietin-like 3 gene expression by repressing HNF-1α activity”. J. Hepatol. 60(1):30-8.
Miltiadous P*, Kouroupi G*, Stamatakis A, Koutsoudaki PN, Matsas R. and F. Stylianopoulou (2013) Subventricular zone-derived neural stem cell grafts protect against hippocampal degeneration and restore cognitive function in the mouse following intrahippocampal kainic acid administration. Stem Cells Transl Med. 2013 2:185-98. *equal contribution
Tsioras K, Papastefanaki F, Politis PK, Matsas R, Gaitanou M. (2013) Functional Interactions between BM88/Cend1, Ran-binding protein M and Dyrk1B kinase affect cyclin D1 levels and cell cycle progression/exit in mouse neuroblastoma cells. PLoS One. 8(11):e82172.
Georganta EM, Tsoutsi L, Gaitanou M and Georgoussi Z. (2013) “δ-opioid receptor activation leads to neurite outgrowth and neuronal differentiation via a STAT5B-Gαi/o pathway” J. Neurochem. 127(3):329-41.
Ziavra D, Makri G, Giompres P, Taraviras S, Thomaidou D, Matsas R, Mitsacos A,Kouvelas ED. Neural stem cells transplanted in a mouse model of Parkinson'sdisease differentiate to neuronal phenotypes and reduce rotational deficit. CNS Neurol Disord Drug Targets. 2012 Nov 1;11(7):829-352012
Lavdas AA, Papastefanaki F, Thomaidou D, Matsas R. (2011) Cell adhesion molecules in gene and cell therapy approaches for nervous system repair. Curr Gene Ther. Apr;11(2):90-100. Review.2011
Kaltezioti V*, Kouroupi G*, Oikonomaki M*, Mantouvalou E, Charonis A, Rohrer H, Matsas R and Politis PK (2010) Prox1 suppresses Notch1 gene expression to regulate neurogenesis in the spinal cord, PLoS Biology, Dec 21;8(12):e1000565 *equal contribution
Makri G, Lavdas AA, Katsimpardi L, Charneau P, Thomaidou D and Matsas R (2010) Transplantation of embryonic neural stem/ precursor cells overexpressing BM88/Cend1 enhances the generation of neuronal cells in the injured mouse cortex. Stem Cells 28:127-39.
Lavdas AA, Chen J, Papastefanaki F, Chen S, Schachner M, Matsas R and Thomaidou D (2010) Schwann cells engineered to express the cell adhesion molecule L1 accelerate myelination and motor recovery after spinal cord injury. Exp Neurol 221:206-16.
Lavdas AA, Efrose R, Douris V, Gaitanou M, Papastefanaki F, Swevers L, Thomaidou D, Iatrou K, Matsas R. (2010) Soluble forms of the cell adhesion molecule L1 produced by insect and baculovirus-transduced mammalian cells enhance Schwann cell motility. J Neurochem. Dec; 115(5):1137-49.
Kouroupi G, Lavdas AA, Gaitanou M, Thomaidou D, Stylianopoulou F, Matsas R. (2010) Lentivirus-mediated expression of insulin-like growth factor-I promotes neural stem/precursor cell proliferation and enhances their potential to generate neurons. J Neurochem. Oct;115(2):460-74.
Sergaki MC, Guillemot F and Matsas R (2010) Impaired cerebellar development and deficits in motor coordination in mice lacking the neuronal protein BM88/Cend1. Mol Cell Neurosci, 44:15–29.
Lavdas A and Matsas R (2009). Schwann cell morphology In: New Encyclopedia of Neuroscience (L.R. Squire, Editor) Oxford: Academic Press, pp 475-484.
Roser M, Hurel C, Papastefanaki F, Georgopoulou N, Thomaidou D and Matsas R (2009) BM88/Cend1 regulates stimuli-induced calcium mobilization. Neuropharmacology, 56:598-609.
Lavdas, AA and Matsas, R (2009) Towards personalized cell-replacement therapies for brain repair Personalized Medicine 6(3): 293-313.
Katsimpardi L, M Gaitanou, CE Malnou, PM Lledo, P. Charneau, R Matsas and D Thomaidou (2008) BM88/Cend1 expression levels are critical for proliferation and differentiation of subventricular zone-derived neural precursor cells. Stem Cells 26:1796-807.
Politis PK, Akrivou S, Hurel C, Papadodima O, Matsas R. (2008) BM88/Cend1 is involved in histone deacetylase inhibition-mediated growth arrest and differentiation of neuroblastoma cells. FEBS Lett. 582:741-8.
Politis PK, Thomaidou D, Matsas R. (2008) Coordination of cell cycle exit and differentiation of neuronal progenitors. Cell Cycle. Mar 15;7(6):691-7.
Sidera K, Gaitanou M, Stellas D, Matsas R, Patsavoudi E. (2008) A critical role for HSP90 in cancer cell invasion involves interaction with the extracellular domain of HER-2. J Biol Chem. 283:2031-41.
Lavdas AA, Papastefanaki F, Thomaidou D, Matsas R (2008) Schwann cell transplantation for CNS repair. Curr Med Chem. 15:151-60.
Politis PK, Makri G, Thomaidou D, Geissen M, Rohrer H, Matsas R. (2007) BM88/CEND1 coordinates cell cycle exit and differentiation of neuronal precursors. Proc Natl Acad Sci U S A. 2104 (45):17861-6.
Papastefanaki F, Chen J, Lavdas AA, Thomaidou D, Schachner M, Matsas R. (2007) Grafts of Schwann cells engineered to express PSA-NCAM promote functional recovery after spinal cord injury. Brain 130:2159-74. (featured article - editorial commentary in Brain (2007), 130:1978-1980)
Politis PK, Rohrer H, Matsas R. (2007) Expression pattern of BM88 in the developing nervous system of the chick and mouse embryo. Gene Expr Patterns 7:165-77.
Gravvanis AI, Lavdas AA, Papalois A, Tsoutsos DA, Matsas R. (2007) The beneficial effect of genetically engineered Schwann cells with enhanced motility in peripheral nerve regeneration Acta Neurochir 100:51-6.
Lavdas AA, Franceschini I, Dubois-Dalcq M, Matsas R. (2006) Schwann cells genetically engineered to express PSA show enhanced migratory potential without impairment of their myelinating ability in vitro. GLIA 53(8):868-78.
Kenoutis C, Efrose RC, Swevers L, Lavdas AA, Gaitanou M, Matsas R, Iatrou K. (2006) Baculovirus-mediated gene delivery into Mammalian cells does not alter their transcriptional and differentiating potential but is accompanied by early viral gene expression. J Virol. 80:4135-46.
Georgopoulou N, Hurel C, Politis PK, Gaitanou M, Matsas R, Thomaidou D. (2006) BM88 is a dual function molecule inducing cell cycle exit and neuronal differentiation of neuroblastoma cells via cyclin D1 down-regulation and retinoblastoma protein hypophosphorylation. J Biol Chem. 281:33606-20.
Gravvanis AI, Lavdas A, Papalois AE, Franceschini I, Tsoutsos DA, Dubois-Dalcq M, Matsas R, Ioannovich JD. (2005) Effect of genetically modified Schwann cells with increased motility in end-to-side nerve grafting. Microsurgery 25:423-32.
Papadodima O, Sergaki M, Hurel C, Mamalaki A, Matsas R. (2005) Characterization of the BM88 promoter and identification of an 88 bp fragment sufficient to drive neurone-specific expression. J Neurochem. 95:146-59.
Koutmani Y, Hurel C, Patsavoudi E, Hack M, Gotz M, Thomaidou D, Matsas R. (2004) BM88 is an early marker of proliferating precursor cells that will differentiate into the neuronal lineage. Eur J Neurosci. 20(10):2509-23.
Meintanis S, Thomaidou D, Jessen KR, Mirsky R, Matsas R. (2004) Novel method for studying myelination in vivo reveals that EDTA is a potent inhibitor of myelin protein and mRNA expression during development of the rat sciatic nerve. Glia. 48(2):132-44.
Thomaidou D, Coquillat D, Meintanis S, Noda M, Rougon G, Matsas R. (2001) Soluble forms of NCAM and F3 neuronal cell adhesion molecules promote Schwann cell migration: identification of protein tyrosine phosphatases zeta/beta as the putative F3 receptors on Schwann cells. J Neurochem. 78(4):767-78.
Gaitanou M, Buanne P, Pappa C, Georgopoulou N, Mamalaki A, Tirone F, Matsas R. (2001) Cloning, expression and localization of human BM88 shows that it maps to chromosome 11p15.5, a region implicated in Beckwith-Wiedemann syndrome and tumorigenesis. Biochem J. 355(Pt 3):715-24.
Meintanis S, Thomaidou D, Jessen KR, Mirsky R, Matsas R. (2001) The neuron-glia signal beta-neuregulin promotes Schwann cell motility via the MAPK pathway. Glia. 34(1):39-51.
Boutou E, Matsas R, Mamalaki A. (2001) Isolation of a mouse brain cDNA expressed in developing neuroblasts and mature neurons. Brain Res Mol Brain Res. 86(1-2):153-67.
Boutou E, Hurel C, Matsas R. (2000) Early expression of the BM88 antigen during neuronal differentiation of P19 embryonal carcinoma cells. Int J Dev Neurosci. 18(2-3):321-8.2000
Gomez J, Boutou E, Hurel C, Mamalaki A, Kentroti S, Vernadakis A, Matsas R. (1998) Overexpression of the neuron-specific molecule BM88 in mouse neuroblastoma cells: altered responsiveness to growth factors. J Neurosci Res. 51(1):119-28.1998
Gaitanou M, Mamalaki A, Merkouri E, Matsas R. (1997) Purification and cDNA cloning of mouse BM89 antigen shows that it is identical with the synaptic vesicle protein synaptophysin. J Neurosci Res. 48(6):507-14.
Matsas R. (1997) Genes controlling neural fate and differentiation. Adv Exp Med Biol. ;429:3-17. Review.
Mamalaki A, Boutou E, Hurel C, Patsavoudi E, Tzartos S, Matsas R. (1995) The BM88 antigen, a novel neuron-specific molecule, enhances the differentiation of mouse neuroblastoma cells. J Biol Chem. 270(23):14201-8.
Kioussi C, Mamalaki A, Jessen K, Mirsky R, Hersh LB, Matsas R. (1995) Expression of endopeptidase-24.11 (common acute lymphoblastic leukaemia antigen CD10) in the sciatic nerve of the adult rat after lesion and during regeneration. Eur J Neurosci. 7(5):951-61.
Patsavoudi E, Merkouri E, Thomaidou D, Sandillon F, Alonso G, Matsas R. (1995) Characterization and localization of the BM88 antigen in the developing and adult rat brain. J Neurosci Res. 40(4):506-18.
Kioussi C, Crine P, Matsas R. (1992) Endopeptidase-24.11 is suppressed in myelin-forming but not in non-myelin-forming Schwann cells during development of the rat sciatic nerve. Neuroscience. 50(1):69-83.1992
Kioussi C, Matsas R. (1991) Endopeptidase-24.11, a cell-surface peptidase of central nervous system neurons, is expressed by Schwann cells in the pig peripheral nervous system. J Neurochem. 57(2):431-40.
Patsavoudi E, Hurel C, Matsas R. (1991) Purification and characterization of neuron-specific surface antigen defined by monoclonal antibody BM88. J Neurochem. 56(3):782-8.
Patsavoudi E, Hurel C, Matsas R. (1989) Neuron- and myelin-specific monoclonal antibodies recognizing cell-surface antigens of the central and peripheral nervous system. Neuroscience. 30(2):463-78.1989
George Skretas| National Research Foundation
Jens Schwamborn| Luxembourg Centre for Systems Biomedicine
Stuart Lipton| The Scripps Research Institute
Ilias Kazanis| Department of Biology, University of Patras
Pauline Speder| Brain Plasticity in Response to the Environment, Institut Pasteur Paris
Shaynoor Dramsi| Laboratory: Biology of Gram-Positive Pathogens, Institut Pasteur Paris
Vivi Miriagou| Laboratory of Bacteriology, Department of Microbiology, Hellenic Pasteur Institute, Athens
Leonidas Stefanis| Biomedical Research Foundation, Academy of Athens
Maria Xilouri| Biomedical Research Foundation, Academy of Athens
Panagiotis Politis| Biomedical Research Foundation, Academy of Athens
Artemis Hatzigeorgiou| DIANA LAB, Hellenic Pasteur Institute, Athens
Ioannis Vlachos| Prof. Patsopoulos Laboratory, Ann Romney Center for Neurological Diseases, Brigham & Women’s Hospital, Harvard Medical School, Boston, MA, USA
Piotr Bregestovski| Aix-Marseille Université, France
Eliezer Masliah| School of Medicine, UC San Diego, USA
Pierre-Marie Lledo| Department of Neuroscience, Institute Pasteur Paris
Chiara Zurzolo| Department of Cell Biology and Infection
Regis Grailhe| Technology Development Platform, Institute Pasteur Korea
Valentina Fossati| The New York Stem Cell Foundation, USA
Panos Douvaras| The New York Stem Cell Foundation, USA
Evan Snyder| Sanford Burham Prebys, Medical Discovery Institute, La Jolla, CA, USA
Melitta Schachner| W.M. Keck Center for Collaborative Neuroscience, Rutgers University, NJ, USA
Igor Jakovcevski| DZNE Bonn/University Hospital of Cologne, Germany
Eleni Douni| “Alexander Fleming” Biomedical Sciences Research Center, Athens
Fotini Stylianopoulou| Faculty of Nursing, University of Athens
Antonis Stamatakis| Faculty of Nursing, University of Athens
Alexandros Lavdas| Researcher, Institute of Biomedicine, EURAC Research, Bolzano, Italy
Panagiotis Politis| Researcher, Biomedical Research Foundation, Academy of Athens
Lida Katsimpardi| Researcher, Department of Neuroscience, Institute Pasteur Paris
Georgia Makri| Post-Doc in Johns Hopkins University (2010-2015)
Maritina Sergaki| Post-Doc Research Institute of Molecular Pathology, Vienna
Konstantinos Tsioras| Post-Doc, Northwestern University Feinberg School of Medicine, Chicago IL, USA
Roser Masgrau| Group Leader, Institut de Neurociencies, Autonomous University of Barcelona
Olga Papadodima| Research Staff Scientist, Metabolic Engineering – Bioinformatics, National Hellenic Research Foundation, Athens
Yassemi Koutmani| Laboratory Technician, Biomedical Research Foundation, Academy of Athens
Chrissa Kioussi| Professor, College of Pharmacy, Oregon State University
Stathis Meintanis| High School Teacher
Efrosini Boutou| Thalassaemia Center, Laiko Hospital, University of Athens
Evangelia Patsavoudi| Professor, Technological Educational Institute of Athens